Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 6/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.65 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.65 |
| ▸ | ADRB3 | P13945 | 8/20 | 0.57 |
| ▸ | DRD2 | P14416 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.57 |
| ▸ | DRD3 | P35462 | 2/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.57 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.57 |
| ▸ | MLNR | O43193 | 1/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3002063 | 0.81 | ADRB2 (0.78) | TLR4ADRB2DNM1ADRB3DRD2 | |
| SCHEMBL3001311 | 0.80 | TLR4 (0.65) | TLR4ADRB2DNM1ADRB3DRD2 | |
| SCHEMBL14542991 | 0.80 | LMNA (0.47) | TLR4NPSR1ADRB2DNM1ADRB3 | |
| SCHEMBL30483431 | 0.80 | ADRB2 (0.72) | TLR4ADRB2DNM1ADRB3DRD2 | |
| SCHEMBL29014917 | 0.80 | ADRB2 (0.72) | TLR4ADRB2DNM1ADRB3DRD2 | |
| Carazolol SCHEMBL6511163 | 0.79 | ADRB2 (1.00) | TLR4ADRB2DNM1ADRB3DRD2 | |
| Carazolol SCHEMBL77903 | 0.79 | ADRB2 (1.00) | TLR4ADRB2DNM1ADRB3DRD2 | |
| Carazolol SCHEMBL77901 | 0.79 | ADRB2 (1.00) | TLR4ADRB2DNM1ADRB3DRD2 | |
| Carazolol SCHEMBL29354289 | 0.79 | ADRB2 (1.00) | TLR4ADRB2DNM1ADRB3DRD2 | |
| SCHEMBL17945967 | 0.78 | ADRB2 (0.64) | TLR4NPSR1ADRB2DNM1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786142-B2 | Heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2010-08-31 | — | — | US | claimed |
| EP-1945612-A2 | HETEROCYCLIC COMPOUNDS AS PSTAT3/IL-6 INHIBITORS | Orchid Research Laboratories Limited (IN) | 2008-07-23 | — | — | EP | claimed |
| US-20070111998-A1 | Novel heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2007-05-17 | — | — | US | claimed |
| WO-2007042912-A2 | HETEROCYCLIC COMPOUNDS AS PSTAT3/IL-6 INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-04-19 | — | — | WO | claimed |
| US-7786142-B2 | Heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2010-08-31 | — | — | US | disclosed |
| US-7786142-B2 | Heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2010-08-31 | — | — | US | disclosed |
| US-7786142-B2 | Heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2010-08-31 | — | — | US | disclosed |
| US-20070111998-A1 | Novel heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2007-05-17 | — | — | US | disclosed |
| US-20070111998-A1 | Novel heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2007-05-17 | — | — | US | disclosed |
| US-20070111998-A1 | Novel heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111998-A1 | Novel heterocyclic compounds as pSTAT3/IL-6 inhibitors | IL6, IL6ST, STAT3 | TLR4 873/4885NPSR1 3418/4885ADRB2 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.